APA (7th ed.) Citation

Kashima, E., Sugimoto, Y., Nagaharu, K., Ohya, E., Ikejiri, M., Watanabe, Y., . . . Tawara, I. Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Kashima, Emiko, Yuka Sugimoto, Keiki Nagaharu, Eiko Ohya, Makoto Ikejiri, Yasuyuki Watanabe, Shinichi Kageyama, Koji Oka, and Isao Tawara. Venetoclax Is Effective for Chronic Myelomonocytic Leukemia Blastic Transformation with RUNX1 Mutation. Taylor & Francis Group.

MLA (9th ed.) Citation

Kashima, Emiko, et al. Venetoclax Is Effective for Chronic Myelomonocytic Leukemia Blastic Transformation with RUNX1 Mutation. Taylor & Francis Group.